Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10240MR)

This product GTTS-WQ10240MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10240MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5413MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ5682MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ12377MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NEOD-001
GTTS-WQ15878MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ6676MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ4646MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ7416MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ12367MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA N63Ab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW